Variable | Group | No. of patients | % |
---|---|---|---|
(n = 10) | |||
Age, years | Median | 52 | |
Range | 23-60 | ||
<50 | 5 | 50 | |
≥50 | 5 | 50 | |
Sex | Men | 7 | 70 |
Women | 3 | 30 | |
Race | Caucasian | 10 | 100 |
Number of prior therapies | Median | 2 | |
Range | 0-5 | ||
≤2 | 8 | 80 | |
>2 | 2 | 20 | |
Lactate dehydrogenasea | ≤upper limit of normal | 9 | 90 |
>upper limit of normal | 1 | 10 | |
TNM stage M1c | No | 6 | 60 |
Yes | 4 | 40 | |
ECOG PS | 0 | 5 | 50 |
1 | 5 | 50 | |
Therapy | BRAF inhibitor alone | 7 | 70 |
MEK inhibitor alone | 1 | 10 | |
BRAF/MEK inhibitor combination | 2 | 20 | |
Treatment response | Complete response | 4 | 40 |
Partial response | 6 | 60 |